title: The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3.
abstract: The receptor activator of nuclear factor kappa B ligand (RANKL) and its decoy receptor, osteoprotegerin (OPG), are important bone metabolism molecules, which directly control osteoclastogenesis. Periodontal ligament (PDL) cells play a vital role in maintaining the homeostasis of periodontal tissues, releasing cytokines to affect bone metabolism. The purpose of this study was to investigate the expression of OPG and RANKL in cultured human periodontal ligament cells (hPDLCs) derived from permanent teeth and the expression change after stimulation by 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)vitD(3)), a kind of bone resorption promoter. HPDLCs were cultured in the presence or absence of 10(-8)M 1alpha,25(OH)(2)vitD(3) in vitro. The expression of mRNA for OPG and RANKL in hPDLCs during 6 days' culture was examined using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). The level of secreted OPG protein in the culture medium during 6 days' culture was detected by enzyme-linked immunoabsorbent assay (ELISA). The result showed that OPG and RANKL were expressed by hPDLCs. OPG expression was down-regulated by 10(-8)M 1alpha,25(OH)(2)vitD(3) in a time-dependent manner, while RANKL mRNA was up-regulated. The ratio of OPG/RANKL was decreased. In conclusion, our findings suggest that hPDLCs may regulate the alveolar bone metabolism through the OPG/RANKL system.
authors.affiliation: Department of Orthodontics, School of Stomatology, Peking University, 100081, Beijing, PR China. dinz@ht.rol.cn.net
authors.forename: D
authors.initials: D
authors.lastname: Zhang
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Yang
authors.forename: X T
authors.initials: XT
authors.lastname: Li
authors.forename: M K
authors.initials: MK
authors.lastname: Fu
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D001641:Bicuspid; D002117:Calcitriol / Q000494:pharmacology*; D002352:Carrier Proteins / Q000235:genetics*; D002478:Cells, Cultured; D002648:Child; D003470:Culture Media / Q000737:chemistry; D005786:Gene Expression Regulation / Q000187:drug effects*; D006023:Glycoproteins / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics*; D053244:Osteoprotegerin; D010513:Periodontal Ligament / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics; D018124:Receptors, Tumor Necrosis Factor; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D002352:Carrier Proteins; D003470:Culture Media; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D002117:Calcitriol